The first annual meeting of the VAC2VAC project was hosted by the Paul-Ehrlich-Institut on 9 and 10 March 2017. The big progress and interest towards animal-free batch to batch vaccine consistency testing was reflected by the productive interaction between academic, industrial and regulatory VAC2VAC partners as well as the strong participation of more than 80 members.
The meeting focused on the progress in method development, including for example physicochemical, immunochemical and cell based methods. Furthermore the roadmap for the next year and the implementation of results via active communication to regulatory authorities was defined.
VAC2VAC is financed for five years by the “Innovative Medicines Initiative” (IMI2), a joint initiative of the European Union and the European Federation of Pharmaceutical Industries and Associations.